Adapting Existing Cooling Containers to Meet Cold Chain Requirements: Insights from Huachiew Chalermprakiet University COVID-19 Vaccination Center
Keywords:
COVID-19, cold chains, inactivated COVID-19 vaccine, non-replicating viral COVID-19 vaccineAbstract
Subsequently, the global pandemic of COVID-19 broke out in 2019, and the COVID-19 vaccine had to be distributed urgently with slightly limited stability data and storage conditions. The cold chains for daily use of inactivated and non-replicating viral COVID-19 vaccines at the Huachiew Chalermprakiet University (HCU) Vaccination Center were developed and validated. The vaccine storage container was studied and validated using adapting existing cooling containers. Storage cold boxes made from plastic/foam with different dimensions for use with ice/ gel packs for the storage of COVID-19 vaccines were optimized for suitable conditions. For the results, it was found that plastic boxes for daily storage vaccine No. 1 (4,209 in3) and No. 2 (2,035 in3) with ice packs 5-6 kg and 2.5-3 kg, respectively, could maintain temperature between 2-8 °C for 8 hours. The prepared vaccine in pre-drawn syringes was stored in a foam box as in a temperature-controlled container No.3 (3,520 in3) with 4 kg of ice pack, which could maintain temperature at 4-6 °C for 7 hours. When using the foam boxes for transferring the pre-drawn vaccines to the vaccination station, it was found that temperature-controlled containers No. 4 (541 in3) and No. 5 (877 in3) with three different conditions of using cooling materials were able to store the pre-drawn vaccines with a temperature between 7-13 °C for 7 hours. All of the results in this study showed the appropriate temperature in vaccine storage containers that meet the cold chain requirement for storage of COVID-19 vaccines.
Downloads
References
Kalinke U, Barouch DH, Rizzi R, Lagkadinou E, Türeci Ö, Pather Sh et al. Clinical development and approval of COVID-19 vaccines. Expert Rev Vaccines. 2022;21(5):609-19. doi: 10.1080/14760584.2022.2042257
The National Health Service. Landmark moment as first NHS patient receives COVID-19 vaccination [internet] 2020. [cited 2024 Aug 4]. Available from: https://www.england.nhs.uk/2020/12/landmark-moment-as-first-nhs-patient-receives-covid-19-vaccination/
Fortner A, Schumacher D. First COVID-19 vaccines receiving the US FDA and EMA emergency use authorization. Discoveries (Craiova). 2021;9(1):e122. doi: 10.15190/d.2021.1
Vaxzevria SmPC. AstraZeneca AB. European medicines agency website [internet]. 2022 [cited 2022 Feb 10]. Available from: https://www.ema.europa.eu/en/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdf
US Food and Drug Administration. Emergency Use Authorization (EUA) for an unapproved product review memorandum [internet]. 2021 [cited 2024 Aug 4]. Available from: https://www.fda.gov/media/146338/download
COVID-19 Vaccine Janssen SmPC. Janssen-Cilag International NV. COVID-19 vaccine Janssen SmPC. European medicines agency website [internet]. Year? [cited 2024 Aug 4]. Available from: https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-janssen-epar-product-information_en.pdf
Science. Russia’s approval of a COVID-19 vaccine is less than meets the press release [internet]. 2020 [cited 2024 Aug 4]. Available from: https://www.science.org/content/article/russia-s-approval-covid-19-vaccine-less-meets-press-release
Kyriakidis NC, López-Cortés A, González EV, et al. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines. 2021;6:28. doi: 10.1038/s41541-021-00292-w
Callaway E. Russia’s fast-track coronavirus vaccine draws outrage over safety. Nature. 2020;584:334–5. doi: 10.1038/d41586-020-02386-2
Tanveer S, Rowhani-Farid A, Hong K, Jefferson T, Doshi P. Transparency of COVID-19 vaccine trials: decisions without data. BMJ Evid Based Med. 2022;27(4):199-205. doi: 10.1136/bmjebm-2021-111735
World Health Organization. WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations [internet]. 2021 [cited 2024 Aug 4]. Available from: https://www.who.int/news/item/01-06-2021-who-validates-sinovac-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations
Fahrni ML, Ismail IA, Refi DM, et al. Management of COVID-19 vaccines cold chain logistics: a scoping review. J Pharm Policy Pract. 2022;15(1):16. doi: 10.1186/s40545-022-00411-5
World Health Organization. COVID-19 Vaccine Explainer. COVID-19 Vaccine (Vero Cell), Inactivated, CoronaVac [internet]. 2021 [cited 2024 Aug 4]. Available from: https://www.who.int/docs/default-source/coronaviruse/act-accelerator/covax/21221_sinovac-vaccine-explainer.pdf?sfvrsn=69283a08_39&download=true
Holm MR, Poland GA. Critical aspects of packaging, storage, preparation, and administration of mRNA and adenovirus-vectored COVID-19 vac cines for optimal efficacy. Vaccine. 2021;39(3):457–9. doi: 10.1016/j.vaccine.2020.12.017
Hfocus. The first batch of Sinovac COVID vaccines has arrived in Thailand. [internet]. 2021 [cited 2024 Aug 3]. Available from: https://www.hfocus.org/content/2021/02/21115
Proceeding of the 2023 FAPA congress; 2023 Oct 26-28; Taipei, Taiwan; c2023.
Xylem.Inc. Use of correct data loggers for vaccines and other sensitive pharmaceutical products [internet]. 2021 [cited 2024 Aug 3]. Available from: https://www.xylem.com/siteassets/brand/ebro/resources/technical-brochure/ebro-tech-note---use-of-correct-data-loggers-for-vaccines.pdf
Supaphan TS, Akanit U, Jinatongthai P, Lapmag An, Sanguanboonyaphong Ph, Donsamak S et al. Pharmacist Guide: To advice on COVID-19 vaccines to the public. 1st ed. Ubon Ratchathani : Faculty of Pharmaceutical Sciences Ubon Ratchathani University; 2011.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Journal of Health Sciences and Wellness

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความที่ได้รับการตีพิมพ์เป็นลิขสิทธิ์ของวารสารวิทยาศาสตร์สุขภาพและสุขภาวะ
ข้อความที่ปรากฏในบทความแต่ละเรื่องในวารสารวิชาการเล่มนี้เป็นความคิดเห็นส่วนตัวของผู้เขียนแต่ละท่านไม่เกี่ยวข้องกับมหาวิทยาลัยหัวเฉียวเฉลิมพระเกียรติ และคณาจารย์ท่านอื่นๆในมหาวิทยาลัยฯ แต่อย่างใด ความรับผิดชอบองค์ประกอบทั้งหมดของบทความแต่ละเรื่องเป็นของผู้เขียนแต่ละท่าน หากมีความผิดพลาดใดๆ ผู้เขียนแต่ละท่านจะรับผิดชอบบทความของตนเองแต่ผู้เดียว
